Association Analysis for Neuronal Nitric Oxide Synthase Gene Polymorphism with Plasma Nitrite/Nitrate Concentration in Schizophrenia

Open access

Summary

Background: Single nucleotide polymorphisms (SNP) of many genes, including the gene for neuronal nitric oxide syn-thase (NOS1), were found significantly associated with schizo-phrenia. According to our previously published results of increased plasma nitric oxide concentration in patients with schizophrenia, we hypothesized that the NOS1 gene polymorphism might be a cause of increased nitric oxide production in patients with schizophrenia and tested the interdependence between plasma nitrite/nitrate concentrations and SNP (a CT transition located in exon 29) of the human NOS1 gene.

Methods: Nitrite/nitrate concentration was measured in blood plasma of 38 patients with schizophrenia and of 39 age and gender matched healthy persons by the colorimet-ric test. The NOS1 gene polymorphism was determined by polymerase chain reaction analysis.

Results: A significantly higher plasma nitrite/nitrate concentration was found in patients with schizophrenia (97.5±33.3 μmol/L, p<0.001) in comparison with controls (61.4±18.9 μmol/L). No T/T genotype was found in healthy individuals and there was a significant difference in the genotype distribution between patients and controls (χ2=24.54, p=0.0000047). Furthermore, a significant difference in the allele frequencies between patients and controls (χ2=19.00, p<0.000013, OR=4.45, 95% CI=2.12–9.39) was noted. Also, a significant difference in plasma nitrite/nitrate concentration was observed between patients having the C/T genotype (99.97±33.83 μmol/L) and the corresponding control (C/T) subgroup (63.88±10.26 μmol/L, p<0.01). However, there were no significant differences in nitrite/nitrate concentration between the patient subgroups with different genotypes (C/C, C/T, T/T).

Conclusions: CT transition located in exon 29 of the human NOS1 gene may be responsible for the increased plasma nitrite/nitrate levels.

1. Russwurm M, Koesling D. Guanyl cyclase: NO hits its target. Biochem Soc Symp 2004; 71: 51–63.

2. Brenman FE, Bredt DS. Synaptic signaling by nitric oxide. Curr Opin Neurobiol 1997; 7: 4–8.

3. Akyol O, Zoroglu SS, Armutcu F, Sahin S, Gurel A. Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In vivo 2004; 18: 77–90.

4. Bernstein H-G, Bogerts B, Keilhoff G. The many faces of nitric oxide in schizophrenia. A review. Schizophrenia Res 2005; 78: 69–86.

5. Kiss J P, Vizi ES. Nitric oxide: A novel link between synap-tic and nonsynaptic transmission. Trends Neurosci 2001; 24: 1–5.

6. Guix FX, Uribesalgo I, Coma M, Munoz FJ. The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 2005; 76: 26–52.

7. Rivier C. Role of gaseous neurotransmitters in the hypo-thalamic-pituitary-adrenal axis. Ann NY Acad Sci 2001; 933: 54–64.

8. Antunes F, Nunes C, Laranjinha J, Cadenas E. Redox interaction of nitric oxide with dopamine and its derivatives. Toxicology 2005; 208: 207–12.

9. Đorđević V V, Stojanović I, Stanković-Ferlež D, Ristić T, Lazarević D, Ćosić V, Đorđević B V. Plasma nitrite/nitrate concentrations in patients with schizophrenia. Clin Chem Lab Med 2010; 48 (1): 89–94.

10. Hara H, Waeber PL, Huang PL, Fujii M, Fishman MC, Moskowitz MA. Brain distribution of nitric oxide synthase in neuronal and endothelial cells of nitric oxide synthase mutant mice using [3H]-L-Nw-nitro-arginine autoradiography. Neuroscience 1996; 75: 81–90.

11. Endres M, Laufs U, Liao JK, Moskowitz MA. Targeting eNOS for stroke protection. Trends Neurosci 2004; 27: 3–9.

12. Andreasen NC, Rezai K, Alliger R, Swayzell VW, Flaum M, Kirchner P, et al. Hypofrontality in neuroleptic-naïve patients and in patients with chronic schizophrenia. Assessment with Xenon-1333 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 1992; 49: 43–58.

13. Sullivan P F, Kendler KS, Neale MC. Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003; 60: 87–92.

14. Reif A, Herterich S, Strobel A, Ehlis AC, Saur D, Jacob C P, et al. A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol Psychiatry 2006; 11: 286–300.

15. Shinkai T, Ohmori O, Hori H, Nakamura J. Allelic association of the neuronal nitric oxyde synthase (NOS1) gene with schizophrenia. Mol Psychiatry 2002; 7: 60–3.

16. Navarro-Gonzalvez JA, Garcia-Benayas C, Arenas J. Semiautomated measurement of nitrate in biological fluids. Clin Chem 1998; 44: 79–81.

17. Ramirez J, Garnica R, Boll M-C, Montes S, Rios C. Low concentration of nitrite and nitrate in cerebrospinal fluid from schizophrenic patients; a pilot study. Schizophr Res 2004; 86: 57–61.

18. Blaise GA, Gauvin D, Gangal M, Authier S. Nitric oxide, cell signaling and cell death. Toxicology 2005; 208: 77–92.

19. Bredt DS, Snyder SH. Nitric oxide, a novel neuronal messenger. Neuron 1992; 8: 3–11.

20. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AMG. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nature Rev 2007; 8: 66–75.

21. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls and controls. Cell 1994; 78: 5–8.

22. Wang Y, Newton DC, Marsden PA. Neuronal NOS: gene structure, mRNA diversity, and functional relevance. Crit Rev Neurobiol 1999; 13: 21–43.

23. Silberberg G, Ben-Shachar D, Navon R. Genetic analysis of nitric oxide synthase 1 variants in schizophrenia and bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2010; 153B (7): 18–28.

24. Shinkai T, Ohmori O, Matsumoto C, Hori H, Kennedy JL, Nakamura J. Genetic association analysis of neuronal nitric oxide gene polymorphism with tardive dyskinesia. Neuromolec Med 2004; 5: 63–70.

25. Wang YC, Liou YJ, Liao DL, Bai YM, Lin C, Yu S, et al. Association analysis of a neural nitric oxide synthase gene polymorphism and antipsychotics-induced tardive dyski-nesia in Chinese schizophrenic patients. J Neural Transm 2004; 111: 3–9.

26. Okumura T, Okochi T, Kishi T, Ikeda M, Kitajima T, Yamanouchi Y, et al. No association between polymorphisms of neuronal oxide synthase 1 gene (NOS1) and schizophrenia in a Japanese population. Neuromolecular Med 2009; 11 (2): 3–7.

27. Brzustowicz LM, Siomne J, Mohseni P, Hayter JE, Hodgkinson KA, Chow E W, et al. Linkage disequilibrium mapping of schizophrenia susceptibility to the CAPON region of chromosome 1q22. Am J Hum Genet 2004; 74: 57–63.

28. Zheng Y, Li H, Quin W, Duan Y, Li C, Zhang J, et al. Association of the carboxyl-terminal PDZ ligand of the neuronal nitric oxide synthase gene with schizophrenia in the Chinese Han population. Biochem Biophys Res Commun 2005; 328: 809–15.

29. O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V, et al. Molecular genetics of schizophrenia collaboration. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008; 40: 3–5.

30. Schanze D, Ekici AB, Gawlik M, Pfuhlmann B, Reis A, Stöber G. Evaluation of risk loci for schizophrenia derived from Genome-Wide Association Studies in a German population. Am J Med Genet Part B 2011; 156: 198–203.

31. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophrenia Res 1998; 32: 9–15.

32. Tošić M, Ott J, Barral S, Bovet P, Deppen P, Gheorghita F, et al. Schizophrenia and oxidative stress: glutamate cys-teine ligase modifier as a susceptibility gene. Am J Hum Genet 2006; 79: 86–92.

33. Kundakovic M. Prenatal programming of psychopathology: The role of epigenetic mechanisms. J Med Biochem 2013; 32: 313–24.

34. Shiino T, Koide T, Kushima I, Ikeda M, Kunimoto S, Nakamura Y, Yoshimi A, Aleksic B, Banno M, Kikuchi T, Kohmura K, Adachi Y, Kawano N, Okada T, Inada T, Hiroski U, Iidaka T, Suzuki M, Iwata N, Ozaki N. Common variants in BCL9 gene and schizophrenia in a Japanese population: association study, meta-analysis and cognitive function analysis. J Med Biochem 2013; 32: 361–7.

35. Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011; 35 (3): 78–93.

36. Šimić G, Lucassen PJ, Krsnik @, Kostović I, Winblad B, Bogdanović N. nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer's disease. Exp Neurol 2000; 165 (1): 12–26.

37. El-Aleem SA, Ragab S, Ahmed R. Upregulation of the inducible nitric oxide synthase in rat hippocampus in a model of Alzheimer's disease: A possible mechanism of aluminium induced Alzheimer's. Egypt J Histol 2008; 32: 73–80.

38. Linares D, Taconis M, Mana P, Correcha M, Fordham S, Staykova M. Neuronal nitric oxide synthase plays a key role in CNS demyelination. J Neurosci 2006; 26 (49): 72–81.

39. Bird DC, Bujas-Bobanović M, Robertson HA, Durson SA. Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase. Psychopharma-cology 2001; 155: 299–309.

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia

Journal Information


IMPACT FACTOR 2018: 2,000
5-year IMPACT FACTOR: 1,075



CiteScore 2018: 1.47

SCImago Journal Rank (SJR) 2018: 0.523
Source Normalized Impact per Paper (SNIP) 2018: 0.581

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 203 163 13
PDF Downloads 79 71 4